Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues:
Total revenues	$ 35,189	$ 38,469	$ 99,971	$ 87,132
Cost of revenues:
Total cost of revenues	21,379	21,335	40,468	42,015
Gross profit	13,810	17,134	59,503	45,117
Operating expenses:
Research and development	42,705	31,123	83,446	58,945
Sales and marketing	9,022	7,428	18,167	14,099
General and administrative	23,216	22,056	49,524	44,189
Total operating expenses	74,943	60,607	151,137	117,233
Loss from operations	(61,133)	(43,473)	(91,634)	(72,116)
Other income (expense):
Gain on equity investments	0	11,828	147,322	11,828
Change in fair value	40,654	(15,700)	76,391	(21,864)
Other income (expense)	4,326	(308)	7,263	31
Total other income (expense)	44,980	(4,180)	230,976	(10,005)
(Loss) income before income taxes	(16,153)	(47,653)	139,342	(82,121)
Income tax (benefit) expense	(20,431)	33	5,928	5
Net income (loss)	$ 4,278	$ (47,686)	$ 133,414	$ (82,126)
Earnings Per Share [Abstract]
Net income (loss) per share of common and limited common stockholders, basic (in USD per share)	$ 0.06	$ (0.67)	$ 1.86	$ (1.15)
Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, basic (in shares)	71,642,722	71,161,892	71,555,395	71,106,470
Net income (loss) per share of common and limited common stockholders, diluted (in USD per share)	$ 0.06	$ (0.67)	$ 1.79	$ (1.15)
Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, diluted: (in shares)	75,064,323	71,161,892	74,499,672	71,106,470
Software products and services
Revenues:
Total revenues	$ 29,352	$ 30,011	$ 61,565	$ 63,092
Cost of revenues:
Total cost of revenues	6,695	7,101	13,810	14,612
Drug discovery
Revenues:
Total revenues	5,837	8,458	38,406	24,040
Cost of revenues:
Total cost of revenues	$ 14,684	$ 14,234	$ 26,658	$ 27,403